The latent membrane protein 2A (LMP2A) of EBV plays a key role in regulating viral latency and EBV pathogenesis by functionally mimicking a constitutively active B cell Ag receptor. When expressed as a B cell-specific transgene in mice, LMP2A drives B cell development, resulting in the bypass of normal developmental checkpoints. In this study, we have demonstrated that expression of LMP2A in transgenic mice results in B cell development that exclusively favors B-1 cells. This switch to B-1 cell development occurs at the pre-B-cell stage of normal B cell development in the bone marrow, a B cell stage much earlier than appreciated for B-1 commitment. This finding indicates that all pre-B cells have the capacity to assume a B-1 cell phenotype if they encounter the appropriate signal during normal development. Furthermore, these studies offer insight into EBV latency and pathogenesis in the human host.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4049/jimmunol.172.9.5329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of micro-nanostructured film with antibacterial, anticorrosive and thermal conductivity properties on copper surface.
Bioelectrochemistry
January 2025
Institute of Marine Science and Technology, Shandong University, Qingdao, Shandong 266237, China. Electronic address:
A micro-nano sharkskin like film (Cu-MNS-FA) was synthesized on copper surface through chemical etching followed by formate passivation, and its anticorrosive, antibacterial and thermal conductivity properties were investigated. Results show that after 7 d of exposure to nature, Pseudomonas aeruginosa and Desulfovibrio vulgaris seawater, the charge transfer resistance of Cu-MNS-FA is more than three times higher than that of unmodified copper. In particular, in D.
View Article and Find Full Text PDFSurface receptor-targeted Protein-based nanocarriers for drug delivery: Advances in cancer therapy.
Nanotechnology
January 2025
Department of Biotechnology, Kalasalingam Academy of Research and Education (Deemed to be University), Anand Nagar, School of Bio, Chemical & Process Enginneering, Krishnankoil, Krishnan Kovil, Tamil Nadu, 626126, INDIA.
Significant progress has been made in cancer therapy with protein-based nanocarriers targeted directly to surface receptors for drug delivery. The nanocarriers are a potentially effective solution for the potential drawbacks of traditional chemotherapy, such as lack of specificity, side effects, and development resistance. Peptides as nanocarriers have been designed based on their biocompatible, biodegradable, and versatile functions to deliver therapeutic agents into cancer cells, reduce systemic toxicity, and maximize therapy efficacy through utilizing targeted ligands such as antibodies, amino acids, vitamins, and other small molecules onto protein-based nanocarriers and thus ensuring that drugs selectively accumulate in the cancer cells instead of healthy organs/drug release at a target site without effects on normal cells, which inherently caused less systemic toxicity/off-target effect.
View Article and Find Full Text PDFLipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies.
ACS Nano
January 2025
Wuya Faculty of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Antidrug antibodies (ADAs) against biologics present a major challenge for sustained biotherapy, including enzyme replacement therapies and adeno-associated virus (AAV) gene therapies. These antibodies arise from undesirable immune responses, leading to altered pharmacokinetics, reduced efficacy, and adverse reactions. In this study, we introduced a rationally designed lipid-rapamycin (Rapa)-based nanovaccine to restore immune tolerance to biologics and overcome drug resistance.
View Article and Find Full Text PDFUsability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study.
JMIR Form Res
January 2025
Department of Medical Informatics, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands.
Background: The prognosis for patients with several types of cancer has substantially improved following the introduction of immune checkpoint inhibitors, a novel type of immunotherapy. However, patients may experience symptoms both from the cancer itself and from the medication. A prototype of the eHealth tool Cancer Patients Better Life Experience (CAPABLE) was developed to facilitate symptom management, aimed at patients with melanoma and renal cell carcinoma treated with immunotherapy.
View Article and Find Full Text PDFExploring P-(Fe,V)-Codoped Metastable-Phase β-NiMoO for Improving the Performance of Overall Water Splitting.
Inorg Chem
January 2025
School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, Zhejiang 315211, P. R. China.
It is especially essential to develop high-performance and low-cost nonprecious metal catalysts for large-scale hydrogen production. A large number of electrochemical catalysts composited by transition metal centers has been reported; however, it is still a great challenge to design and manipulate target electrocatalysts to realize high overall water-splitting activity at the atomic level. Herein, we develop totally new P-(Fe,V)-codoped metastable-phase β-NiMoO.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!